MeiraGTx Initiated with Buy Rating and $50 Price Target by Lucid Capital

Lucid Capital initiated coverage of MeiraGTx (MGTX) with a Buy rating and $50 price target, citing the company's development of next-generation genetic medicines to potentially unlock cures in chronic diseases. The firm believes MeiraGTx is providing a toolbox to pharma, enabling it to unlock new treatments.

Lucid Capital has initiated coverage of MeiraGTx (MGTX) with a Buy rating and set a target price of $50. According to an analyst at the firm, MeiraGTx focuses on advancing genetic medicine, aiming to provide potential treatments for chronic diseases. The company is described as offering a valuable toolkit for the pharmaceutical industry, enhancing the development of innovative therapies [1].

Based on the one-year price targets offered by 5 analysts, the average target price for MeiraGTx Holdings PLC (MGTX) is $23.00, with a high estimate of $35.00 and a low estimate of $13.00. The average target implies an upside of 283.33% from the current price of $6.00 [1]. The consensus recommendation from 5 brokerage firms is currently 1.8, indicating an "Outperform" status [1].

Lucid Capital believes MeiraGTx is providing a toolbox to the pharmaceutical industry, enabling it to unlock new treatments. The company's focus on genetic medicine is seen as a significant advancement in the field, with potential to address chronic diseases that currently lack effective treatments [1].

References:
[1] https://www.gurufocus.com/news/2914751/lucid-capital-initiates-buy-rating-on-meiragtx-mgtx-with-50-target-mgtx-stock-news